You will be involved in the clinical evaluation of novel PET tracers monitoring the effects of immune therapy. The project will focus on the validation of immune cell tracers (e.g., CD8) in relation to systemic and tumor effects using immunohistochemistry and FACS analyses. In addition, (automated) quantification of tracer uptake and (PBPK) modeling to understand the biological underpinnings will be used.
You will work on a highly multidisciplinary project that aims at the development of ‘fit for purpose’ immune therapy PET tracers. Specifically, you will use clinical molecular imaging data in combination with numerous methods (i.e., AI image analyses, PBPK modeling, immunohistochemistry, FACS).
As a postdoctoral researcher, you are committed to conducting independent and original scientific research, reporting on this research in international publications and presentations. You will take initiatives with grant applications to secure additional funding.
We are looking for a highly ambitious, motivated, and enthusiastic postdoctoral researcher with a strong background in molecular imaging and/or immunology. You have a creative, open and resilient mind, excellent interpersonal skills combined with the ability to work efficiently both independently and as part of a team. Moreover, you have:
Watch this video with more information about joining Amsterdam UMC Research BV.
Amsterdam UMC Research BV supports non-profit scientific research. In doing so, we provide researchers with everything they need to excel. Our principal investigators (PIs) and project leaders offer support in the field of project management, finance and human resources. In medical scientific research projects, legal support is also provided.
Watch the video to find out more.
The Amsterdam University Medical Center's medical oncology department's mission is to improve the life expectancy and quality of life of cancer patients through personalized therapy—the right systemic treatment for each individual patient. Research in the department focuses on novel, individualized treatment strategies in the field of targeted agents and immunotherapy, either alone or in combination with conventional chemotherapy. Furthermore, innovative methods are developed to accurately and early determine the effect of treatment. Our department is characterized by conducting translational research with continuous interaction between researchers in the laboratory and the clinic. To select the right treatment for each individual patient, the department conducts research into molecular imaging, a promising method for non-invasively studying specific tumor characteristics across all tumor sites.
The project leader at Amsterdam UMC is Prof. Dr. Willemien Menke-van der Houven van Oordt, a medical oncologist. You will be part of her research team investigating diverse aspects of clinical molecular imaging for diagnostics, drug development, and immune monitoring. There will be close contact with the nuclear medicine department (Prof Dr. Ronald Boellaard/ Dr. M. Huisman) and colleagues at other centers. Working at Amsterdam UMC, VUmc location, means working in an inspiring and professional environment where developing talents and skills is strongly encouraged. We offer many opportunities for personal development, deepening and broadening your knowledge, additional courses, and a place to grow.
During the publication period, applications will be handled continuously. If the vacancy is filled, it will be closed prematurely.
If you have any questions about this position, please feel free to contact C.W. Menke-van der Houven van Oordt, project manager, at +31 20 444 4321 or secretariaat.oncologie@amsterdamumc.nl.
For more information about the application procedure, please contact Rhiannon Sandfort, recruitment advisor, via r.e.sandfort@amsterdamumc.nl.
A reference check, screening and hiring test may be part of the procedure. Read here whether that applies to you. If you join us, we ask you for a VOG (Certificate of Good Conduct).
Internal candidates will be given priority over external candidates in case of equal suitability.
Acquisition in response to this vacancy will not be considered.